Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation

American Journal of Transplantation

Volumn 5, Issue 12, 2005, Pages 2961-2967

  Lake, J R ^a,b   David, K M ^c   Steffen, B J ^c   Chu, A H ^c   Gordon, R D ^d   Wiesner, R H ^e  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c ProSanos Corporation   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Immunosuppression; Liver transplant; Malignancy; MMF; Survival; Tacrolimus

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; AGE; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; UNITED STATES; ADOLESCENT; DRUG COMBINATION; GRAFT REJECTION; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASM; STATISTICS; SURVIVAL;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASMS; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 33644820721     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01117.x     Document Type: Article

References (23)

1. Herrero JI Luceno JF Quiroga J et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 2003 3 : 1407 1412.
2. Herrero JI Lorenzo M Quiroga J et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005 11 : 89 97.
3. Xiol X Guardiola J Menendez S et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001 7 : 971 975.
4. Benlloch S Berenguer M Prieto M et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004 4 : 596 604.
5. Jimenez C Rodriguez D Marques E et al. De novo tumors after orthotopic liver transplantation. Transplant Proc 2002 34 : 297 298.
6. Pruthi J Medkiff KA Erason KT et al. Analysis of cause of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001 7 : 811 815.
7. Sheiner PA Magliocca JF Bodian CA Kim-Schluger L Altaca G Guarrera JV. Long term medical complications in patients surviving ≥5 years after liver trasnsplantation. Transplantation 2000 69 : 781 789.
8. Hojo M Morimoto T Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1997 397 : 530 534.
9. Fung JJ Jain A Kwak EJ Kusne S Dvorchik I Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001 11 ( Suppl. 1 S109 S118.
10. Funch DP Ko HH Travasso J et al. Association between mycophenolate mofetic (MMF) and development of post-transplant lymphoproliferative disorders in renal transplant patients in the U.S. Am J Transplant 2003 3 ( Suppl. 5 348.
11. Robson RA Opelz G Cecka JM Shah E Sacks S Budde M. Risk of PTLD and other malignancies in renal transplant patients treated with MMF: A prospective observational cohort study. (Abstract 139). Am J Transplant 2003 3 ( Suppl. 5 187.
12. Dharnidharka VR Ho PL Stablein DM Harmon WE Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002 6 : 396 369.
13. Dantal J Soulillou J-P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005 352 : 1371 1373.
14. Jonas S Rayes N Neumann U et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997 80 : 1141 1150.
15. Duvoux C Pageaux GP Vanlemmens C et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 pateints. Transplantation 2002 74 : 1103 1109.
16. Berenguer M Prieto M Bustamanti M et al. Incidence of de novo neoplasms after liver transplantation. Med Clin 1998 111 : 481 484.
17. Haagsma EB Hagens VE Schaapveld M et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001 34 : 84 91.
18. Saigal S Norris S Muiesan P Rela M Heaton N O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002 8 : 482 487.
19. Catena F Nardo B d'Arcangelo G et al. De novo malignancies after organ transplantation. Transplant Proc 2001 33 : 1858 1859.
20. Agraharkar ML Cinclair RD HKuo YF Daller JA Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004 66 : 383 389.
21. Swinnen L Costanzo-Nordin M Fisher S et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990 323 : 1723 1728.
22. Dickinson DM Ellison MD Webb RL. Data sources and structure. Am J Transplant 2003 3 ( Suppl. 4 13 28.
23. van Gelder T Klupp J Barten MJ Christians U Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001 12 : 119 128.